--- title: "Teva Pharmaceutical Industries (TEVA) news: bankruptcy" url: "https://aibio.space/companies/teva-pharmaceutical-industries/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "TEVA bankruptcy news. Teva Pharmaceutical Industries news for investors: Teva is an Israel-based drugmaker that sells generic medicines and biosimilars…" --- Desk view · Opinion · Updated Oct 22, 2026 ## Teva's branded drugs carry the story as generics shrink Teva's branded drugs are growing fast enough to offset falling generics sales for now, and the pipeline has an approval in hand and another FDA decision due in early 2027. The open questions are the 2027 Austedo price change, the cost of the new government pricing deal and whether duvakitug holds up in phase 3. Read the full desk view aibio.space Investor Rank · Opinion **7** /10 Positive view Branded drugs are offsetting falling generics with an approval in hand, while $12.9 billion of net debt and the 2027 Austedo Medicare price are the main pressures. - **Technology**: 2/2 - **Odds**: 2/2 - **Balance sheet**: 1/2 - **Risk**: 1/2 - **Momentum**: 1/2 Opinion only. The Investor Rank is aibio.space's opinion of the company's business position, drawn from the public sources on this page. It is not a recommendation to buy, sell or hold any security and it is not investment advice. It does not consider the share price, valuation or your circumstances, and it can change at any time. Payments from companies never affect it. [How the rank works](https://aibio.space/disclosures/#rank). - **Technology**: **Known drugs, new forms.** Teva's growth comes from reformulations such as Weltruza and from antibodies against TL1A and IL-15, alongside a large generics and biosimilars business. - **Odds**: **Good near term.** Weltruza is approved and ecopipam is under priority review, while duvakitug is in phase 3 after uncontrolled 44-week phase 2b data. - **Balance sheet**: **Leveraged but improving.** Net debt was $12.9 billion at June 30, 2026, and Teva refinanced about $4.9 billion of notes in September after returning to investment grade. - **Main risk**: **Pricing pressure on Austedo.** Its Medicare negotiated price starts on Jan. 1, 2027, and a new Medicaid agreement adds pricing commitments with undisclosed terms. - **Watch next**: **November events.** Third-quarter results on Nov. 3, the R&D Day on Nov. 11 and the Nov. 14 FDA date for the BioXcel drug Teva bid for. ## Top news on Teva 1. 2026-08-28 Distress [Teva bids $57.5 million upfront for BioXcel's agitation drug in bankruptcy sale](https://aibio.space/news/teva-bids-57-5-million-upfront-bioxcels-agitation-drug-bankruptcy-sale/) Teva is the stalking horse bidder for BioXcel's dexmedetomidine film, which faces an FDA decision on at-home use by Nov. 14. Other bidders can still top the offer. 2. 2026-08-27 Distress [BioXcel files Chapter 11 with Teva as $57.5 million stalking horse bidder](https://aibio.space/news/bioxcel-files-chapter-11-teva-57-5-million-stalking-horse-bidder/) BioXcel filed Chapter 11 on Aug 27 with Teva's $57.5 million upfront bid as the floor for a court auction. That upfront sum is below the company's $107,152 thousand of total debt at June 30. ## Dates **November 3, 2026** Third-quarter 2026 results and conference call [Source](https://www.tevapharm.com/news-and-media/latest-news/teva-to-host-conference-call-to-discuss-third-quarter-2026-financial-results-on-november-3-2026-at-8-a.m) **November 11, 2026** R&D Day in New York [Source](https://www.tevapharm.com/news-and-media/latest-news/teva-to-host-rd-day-on-wednesday-november-11-in-new-york-city/) **November 14, 2026** FDA action date for at-home use of dexmedetomidine sublingual film, the BioXcel asset Teva bid for [Source](https://www.tevapharm.com/news-and-media/latest-news/tevaannouncesproposedacquisition-ofanovel-neuroscienceproductreinforcing-disciplined-business-deve/) **Q4 2026** Planned start of a phase 2 study of TEV '408 in vitiligo [Source](https://www.sec.gov/Archives/edgar/data/818686/000117184326004974/exh_991.htm) **Late Q1 2027** FDA action date for ecopipam in pediatric Tourette syndrome [Source](https://www.tevapharm.com/news-and-media/latest-news/u.s.-fda-accepts-tevas-new-drug-application-nda-and-grants-priority-review-for-ecopipam-a-first-in-cl) ## The money Cash and cash equivalents of $3,655 million and total debt of $16,593 million at June 30, 2026 (net debt $12,938 million). 2026 free cash flow guidance of $2.0 billion to $2.4 billion. [Source](https://www.sec.gov/Archives/edgar/data/818686/000117184326004974/exh_991.htm) Second-quarter 2026 revenue of $4,142 million, down 1% in U.S. dollars. Austedo $696 million, Ajovy $244 million, Uzedy $77 million. 2026 revenue guidance $16.5 billion to $16.85 billion. [Source](https://www.sec.gov/Archives/edgar/data/818686/000117184326004974/exh_991.htm) ## Risks on the record - Medicare negotiated prices for Austedo and Austedo XR take effect on Jan. 1, 2027 for eligible Medicare patients. [Source](https://www.sec.gov/Archives/edgar/data/818686/000119312526323619/d118828d10q.htm) - Global generics revenue fell 15% in local currency in Q2 2026, mainly from competition for lenalidomide capsules in the U.S. [Source](https://www.sec.gov/Archives/edgar/data/818686/000117184326004974/exh_991.htm) - Debt was $16,593 million at June 30, 2026, and financial leverage (debt to debt plus equity) was 68%. [Source](https://www.sec.gov/Archives/edgar/data/818686/000117184326004974/exh_991.htm) ## Questions investors ask ### What is aibio.space's Investor Rank for Teva Pharmaceutical Industries? 7 out of 10, our positive view. Branded drugs are offsetting falling generics with an approval in hand, while $12.9 billion of net debt and the 2027 Austedo Medicare price are the main pressures. This is opinion only, not a recommendation to buy, sell or hold, and it does not consider the share price or valuation. [Source](https://aibio.space/disclosures/#rank) ### What did the FDA approve for Teva in October 2026? On Oct. 9, 2026 the FDA approved Weltruza, a once-monthly subcutaneous olanzapine injection for adults with schizophrenia. It needs no loading doses, oral supplementation or post-injection monitoring. [Source](https://www.tevapharm.com/news-and-media/latest-news/teva-announces-u.s.-food-and-drug-administration-fda-approval-of-weltruza-olanzapine-for-extended-re) ### How much revenue did Teva report for Q2 2026? Teva reported second-quarter 2026 revenue of $4,142 million, down 1% in U.S. dollars from a year earlier. Austedo, Ajovy and Uzedy together brought in more than $1 billion. [Source](https://www.sec.gov/Archives/edgar/data/818686/000117184326004974/exh_991.htm) ### What is duvakitug and what stage is it in? Duvakitug is an anti-TL1A antibody that Teva co-develops with Sanofi for ulcerative colitis and Crohn's disease. It is in four phase 3 trials, and 44-week phase 2b maintenance data were presented in October 2026. [Source](https://www.tevapharm.com/news-and-media/latest-news/ueg-week-teva-and-sanofis-duvakitug-maintained-long-term-positive-outcomes-in-new-phase-2b-data-for-ulc/) ### How much did Teva pay for Emalex Biosciences? Teva agreed in April 2026 to pay $700 million in cash for Emalex, with up to $200 million more in commercial milestones and royalties on ecopipam sales. Ecopipam's FDA action date is late in the first quarter of 2027. [Source](https://www.tevapharm.com/news-and-media/latest-news/teva-acquire-emalex-biosciences/) ### When does Teva report third-quarter 2026 earnings? Teva will release third-quarter 2026 results on Nov. 3, 2026 at 7:00 a.m. ET, followed by a conference call at 8:00 a.m. ET. [Source](https://www.tevapharm.com/news-and-media/latest-news/teva-to-host-conference-call-to-discuss-third-quarter-2026-financial-results-on-november-3-2026-at-8-a.m) ### What is the latest Teva Pharmaceutical Industries (TEVA) stock news? Our latest story on Teva Pharmaceutical Industries, dated Aug 28, 2026: "Teva bids $57.5 million upfront for BioXcel's agitation drug in bankruptcy sale". Teva is the stalking horse bidder for BioXcel's dexmedetomidine film, which faces an FDA decision on at-home use by Nov. 14. Other bidders can still top the offer. [Source](https://aibio.space/news/teva-bids-57-5-million-upfront-bioxcels-agitation-drug-bankruptcy-sale/) ### How much cash does Teva Pharmaceutical Industries have? From our story of Aug 28, 2026: In April it agreed to acquire Emalex Biosciences for $700 million in cash, plus up to $200 million in commercial milestones and royalties, to get ecopipam for pediatric Tourette syndrome. [Source](https://aibio.space/news/teva-bids-57-5-million-upfront-bioxcels-agitation-drug-bankruptcy-sale/) ### Is Teva Pharmaceutical Industries in financial distress? Our latest distress story, dated Aug 28, 2026: "Teva bids $57.5 million upfront for BioXcel's agitation drug in bankruptcy sale". Teva is the stalking horse bidder for BioXcel's dexmedetomidine film, which faces an FDA decision on at-home use by Nov. 14. Other bidders can still top the offer. [Source](https://aibio.space/news/teva-bids-57-5-million-upfront-bioxcels-agitation-drug-bankruptcy-sale/) ### What is Teva Pharmaceutical Industries's market cap? We do not publish live share prices. In its annual report, Teva Pharmaceutical Industries Limited put the market value of shares held by non-affiliates (public float) at $18.16 billion as of Jun 30, 2025. Source ### Is Teva Pharmaceutical Industries a smaller reporting company? SEC records list Teva Pharmaceutical Industries Limited's filer category as: Large accelerated filer. Source ### Where is Teva Pharmaceutical Industries headquartered? SEC records list its business address as TEVA PHARMACEUTICAL INDUSTRIES LIMITED, TEL AVIV. Source ### When does Teva Pharmaceutical Industries's fiscal year end? Teva Pharmaceutical Industries Limited's fiscal year ends on December 31, per SEC records. Source ### What did Teva Pharmaceutical Industries last file with the SEC? Its most recent filing in our record is an 8-K filed 2026-09-16. All of its filings are on SEC EDGAR. [Source](https://www.sec.gov/Archives/edgar/data/818686/000119312526393116/d155511d8k.htm) ### What was Teva Pharmaceutical Industries called before? SEC records list these former names: TEVA PHARMACEUTICAL INDUSTRIES LIMITED. Source ## Legal and investor matters Checked against Teva Pharmaceutical Industries filings and press releases. Allegations are allegations; nothing here is a finding of fault. Reviewed Oct 25, 2026. 1. 2026-09-16 Financing Teva subsidiaries issue euro and dollar senior notes on 2026-09-16 On 2026-09-16 three Teva finance subsidiaries issued senior notes: 1.0 billion euros of 4.250% notes due 2033, 500 million euros of 4.625% notes due 2036, and US dollar notes of 1.0 billion due 2034, 1.0 billion due 2037 and 1.2 billion due 2032. Teva said net proceeds would fund redemptions of certain existing notes, fees, and general corporate purposes, including repaying debt. [Teva 8-K filed 2026-09-16](https://www.sec.gov/Archives/edgar/data/818686/000119312526393116/d155511d8k.htm) 2. 2026-09-14 Governance Teva ordinary shares begin trading on NYSE as ADS program ends Teva began trading its ordinary shares on the New York Stock Exchange on 2026-09-14 in place of its American depositary shares, under the same ticker TEVA. The ADS program terminated that day and each ADS was exchanged for one ordinary share. The shares continue to trade on the Tel Aviv Stock Exchange. An amendment to the deposit agreement dated 2026-08-31 provided for the mandatory exchange. [Teva 8-K filed 2026-09-14](https://www.sec.gov/Archives/edgar/data/818686/000119312526390562/d503082d8k.htm) 3. 2026-07-29 Class action Teva reaches agreement in principle in Copaxone securities class action Teva's 10-Q filed July 29, 2026 says that in May 2026 the parties to a putative securities class action in the Eastern District of Pennsylvania reached an agreement in principle to resolve the case. The amended complaint alleges that Teva and certain current and former officers violated federal securities laws by allegedly making false and misleading statements about Copaxone, including by failing to disclose that Teva had allegedly caused the submission of false claims to Medicare through donations to charities. The putative class period is October 29, 2015 to August 18, 2020. Teva recognized a provision in the second quarter of 2026, a portion of which is expected to be covered by insurance. U.S. District Court, Eastern District of Pennsylvania · Status: pending [Teva 10-Q for the quarter ended 2026-06-30](https://www.sec.gov/Archives/edgar/data/818686/000119312526323619/d118828d10q.htm) 4. 2026-07-29 Litigation Generic drug price-fixing litigation: Teva reaches deals with indirect resellers Teva reported that as of July 2026 all manufacturer defendants, including Teva and Actavis, reached agreements in principle to settle the indirect reseller plaintiffs' claims in the generic drug multidistrict litigation in the Eastern District of Pennsylvania. The December 2026 trial is no longer expected. Teva recorded provisions in the second quarter of 2026. The complaints allege price fixing and market allocation. Claims by state attorneys general and opt-out plaintiffs remain pending. U.S. District Court, Eastern District of Pennsylvania (MDL) · Status: pending [Teva 10-Q for the quarter ended 2026-06-30](https://www.sec.gov/Archives/edgar/data/818686/000119312526323619/d118828d10q.htm) 5. 2026-06-13 Litigation Court preliminarily approves Teva opioid settlement with third-party payers Teva's 10-Q filed July 29, 2026 says that on 2026-06-13 the court in the opioid multidistrict litigation in the Northern District of Ohio granted preliminary approval to Teva's settlement with a class of third-party payers and scheduled a fairness hearing for 2026-09-23. Teva reached the agreement in principle in the first quarter of 2026. The settlement is contingent on Teva's satisfaction, in its sole discretion, with the level of participation by the third-party payers. The filing says Teva has recorded a provision for its opioid settlements. U.S. District Court, Northern District of Ohio (MDL) · Status: pending [Teva 10-Q for the quarter ended 2026-06-30](https://www.sec.gov/Archives/edgar/data/818686/000119312526323619/d118828d10q.htm) 6. 2026-05-26 Regulatory Government declines to intervene in qui tam over former Irvine plant On 2026-05-26 the government notified the U.S. District Court for the District of Massachusetts of its decision not to intervene in a False Claims Act qui tam complaint filed under seal by a former employee. The complaint was unsealed on 2026-05-27, and the plaintiff has 90 days to effect service if she intends to pursue the litigation. Teva says that a civil investigative demand it received on 2024-10-01 from the U.S. Attorney's office in Boston and the DOJ Civil Division, requesting information on manufacturing practices at its former Irvine, California facility (closed in 2022), arose from that complaint. U.S. District Court, District of Massachusetts · Status: pending [Teva 10-Q for the quarter ended 2026-06-30](https://www.sec.gov/Archives/edgar/data/818686/000119312526323619/d118828d10q.htm) 7. 2025-05-28 Financing Teva subsidiaries issue euro and dollar senior notes to fund tender offer On 2025-05-28 three Teva finance subsidiaries issued senior notes: 1.0 billion euros of 4.125% notes due 2031, $500 million of 6.000% notes due 2032, and a series of 5.750% notes due 2030. Teva said it intends to use the net proceeds to fund a tender offer for a maximum combined aggregate purchase price of up to $2.25 billion (upsized from a previously announced cap of $2.0 billion), to pay fees and expenses, and, with any remainder, to repay outstanding debt. [Teva 8-K filed 2025-05-28](https://www.sec.gov/Archives/edgar/data/818686/000119312525129488/d918164d8k.htm) 8. 2025-01-15 Litigation Teva challenges Medicare drug price negotiation rules; loses at district court On 2025-01-15 Teva sued the Centers for Medicare and Medicaid Services in federal court in Washington, DC, alleging that CMS's implementation of the Inflation Reduction Act drug price negotiation program is arbitrary and unconstitutional. The court granted CMS summary judgment on 2025-11-20. Teva appealed, the appeal was heard on 2026-05-05, and a decision remains pending according to the second quarter 2026 10-Q. U.S. District Court, District of Columbia · Status: appealed [Teva 10-Q for the quarter ended 2026-06-30](https://www.sec.gov/Archives/edgar/data/818686/000119312526323619/d118828d10q.htm) 9. 2024-10-31 Regulatory European Commission fines Teva 462.6 million euros over alleged Copaxone anticompetitive practices On 2024-10-31 the European Commission issued a final decision alleging that Teva engaged in anticompetitive practices on Copaxone in certain member states, by filing and withdrawing certain divisional patents and by raising concerns about competitors' follow-on versions, and imposed a fine of 462.6 million euros. Teva filed an appeal with the General Court of the European Union in January 2025, which the 10-Q filed July 29, 2026 says remains pending. Teva has given the Commission surety guarantees covering the fine. Certain generic competitors have brought follow-on antitrust damages claims against Teva in Germany and the Netherlands, which have been stayed. General Court of the European Union · Status: appealed [Teva 10-Q for the quarter ended 2026-06-30](https://www.sec.gov/Archives/edgar/data/818686/000119312526323619/d118828d10q.htm) ## Pipeline | Program | Indication | Stage | |---|---|---| | Weltruza (olanzapine extended-release, TEV-'749) | Schizophrenia in adults | FDA approved Oct. 9, 2026; EU application accepted May 2026 [Source](https://www.tevapharm.com/news-and-media/latest-news/teva-announces-u.s.-food-and-drug-administration-fda-approval-of-weltruza-olanzapine-for-extended-re) | | Duvakitug (anti-TL1A, with Sanofi) | Ulcerative colitis and Crohn's disease | Phase 3 (SUNSCAPE-1 and -2, STARSCAPE-1 and -2); phase 2 in hidradenitis suppurativa [Source](https://www.tevapharm.com/news-and-media/latest-news/ueg-week-teva-and-sanofis-duvakitug-maintained-long-term-positive-outcomes-in-new-phase-2b-data-for-ulc/) | | Ecopipam (EBS-101) | Pediatric Tourette syndrome | NDA accepted with priority review; PDUFA date late in Q1 2027 [Source](https://www.tevapharm.com/news-and-media/latest-news/u.s.-fda-accepts-tevas-new-drug-application-nda-and-grants-priority-review-for-ecopipam-a-first-in-cl) | | TEV '408 (anti-IL-15) | Celiac disease; vitiligo | Phase 2a celiac met primary endpoint (Sept. 2026); phase 2 vitiligo planned [Source](https://www.tevapharm.com/news-and-media/latest-news/teva-announces-positive-topline-results-from-phase-2a-study-in-celiac-disease-for-its-anti-il-15-antibody/) | | Dexmedetomidine sublingual film (BXCL501) | At-home acute agitation in schizophrenia or bipolar disorder | Stalking horse bid in BioXcel sale; FDA action date Nov. 14, 2026 [Source](https://www.tevapharm.com/news-and-media/latest-news/tevaannouncesproposedacquisition-ofanovel-neuroscienceproductreinforcing-disciplined-business-deve/) | ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open TASE:TEVA on TradingView](https://www.tradingview.com/symbols/TASE-TEVA/). ## SEC filings and registration - **SEC name**: Teva Pharmaceutical Industries Ltd - **CIK**: 818686 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: TEVA (NYSE) - **State or country of incorporation**: L3 - **Fiscal year ends**: December 31 - **Filer category**: Large accelerated filer - **Business address**: TEVA PHARMACEUTICAL INDUSTRIES LIMITED, TEL AVIV - **Phone**: 972 (3) 914-8213 - **Shares outstanding**: 1,165,296,084 as of 2026-06-30 (10-Q filed 2026-07-29) - **Former names**: TEVA PHARMACEUTICAL INDUSTRIES LIMITED ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/818686/000119312526393116/d155511d8k.htm) filed 2026-09-16 - [8-K](https://www.sec.gov/Archives/edgar/data/818686/000119312526390562/d503082d8k.htm) filed 2026-09-14 - [424B5](https://www.sec.gov/Archives/edgar/data/818686/000119312526389382/d158426d424b5.htm) filed 2026-09-11 - [8-K](https://www.sec.gov/Archives/edgar/data/818686/000119312526389264/d81245d8k.htm) filed 2026-09-11 - [424B5](https://www.sec.gov/Archives/edgar/data/818686/000119312526384343/d158426d424b5.htm) filed 2026-09-08 - [8-K](https://www.sec.gov/Archives/edgar/data/818686/000119312526381899/d153033d8k.htm) filed 2026-09-03 - [8-K](https://www.sec.gov/Archives/edgar/data/818686/000119312526381879/d174614d8k.htm) filed 2026-09-03 - [10-Q](https://www.sec.gov/Archives/edgar/data/818686/000119312526323619/d118828d10q.htm) filed 2026-07-29 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000818686), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/teva-pharmaceutical-industries/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Teva Pharmaceutical Industries (TEVA) news: bankruptcy", 2026-10-31, https://aibio.space/companies/teva-pharmaceutical-industries/